CAG
PMCB icon

Csenge Advisory Group’s PharmaCyte Biotech PMCB Stock Holding History

Csenge Advisory Group’s Portfolio PMCB Stock Details PMCB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-200,104
Closed -$480K – 645
2022
Q3 		$480K Buy
+200,104
New +$506K 0.04% 349

Other funds holding PMCB

AC
Ayrton Capital Westport, Connecticut $14.7M AUM 12.82% 1-Year Est. Return
KPF
K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EPM
Equitec Proprietary Markets Chicago, Illinois $559M AUM 230.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
IEFM
IQ EQ Fund Management Dublin 2, Ireland $1.32B AUM 31.52% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Csenge Advisory Group's PMCB Position: Q4 2022 in Review

Csenge Advisory Group sold out of PharmaCyte Biotech (PMCB) in Q4 2022, closing a stake of 200,104 shares — an estimated $480K sold.

Csenge Advisory Group first reported a position in PMCB in Q3 2022 and held it in 1 quarter. The position peaked at $480K in Q3 2022. 30 funds tracked by Wall St. Rank hold PMCB as of Q4 2022.

  • Csenge Advisory Group reported no remaining PharmaCyte Biotech position as of Q4 2022 after selling out during the quarter.
  • Csenge Advisory Group sold 200,104 PharmaCyte Biotech shares in Q4 2022, an estimated $480K.
  • Csenge Advisory Group first reported a position in PharmaCyte Biotech in Q3 2022 and held it in 1 quarter.
  • Csenge Advisory Group's PharmaCyte Biotech position peaked at $480K in Q3 2022.
  • 30 funds tracked by Wall St. Rank held PharmaCyte Biotech as of Q4 2022.

Based on Csenge Advisory Group's 13F filing for Q4 2022, filed 10 Feb 2023.